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SURF1 deficiency causes demyelinating
Charcot-Marie-Tooth disease
ABSTRACT
Objective: To investigate whether mutations in the SURF1 gene are a cause of Charcot-Marie-
Tooth (CMT) disease.
Methods: We describe 2 patients from a consanguineous family with demyelinating autosomal
recessive CMT disease (CMT4) associated with the homozygous splice site mutation
c.107-2A.G in the SURF1 gene, encoding an assembly factor of the mitochondrial respiratory
chain complex IV. This observation led us to hypothesize that mutations in SURF1 might be an
unrecognized cause of CMT4, and we investigated SURF1 in a total of 40 unrelated patients with
CMT4 after exclusion of mutations in known CMT4 genes. The functional impact of c.107-2A.G
on splicing, amount of SURF1 protein, and on complex IV activity and assembly was analyzed.
Results: Another patient with CMT4 was found to harbor 2 additional SURF1 mutations. All
3 patients with SURF1-associated CMT4 presented with severe childhood-onset neuropathy,
motor nerve conduction velocities ,25 m/s, and lactic acidosis. Two patients had brain MRI
abnormalities, including putaminal and periaqueductal lesions, and developed cerebellar ataxia
years after polyneuropathy. The c.107-2A.G mutation produced no normally spliced transcript,
leading to SURF1 absence. However, complex IV remained partially functional in muscle and
fibroblasts.
Conclusions:We found SURF1mutations in 5% of families (2/41) presenting with CMT4. SURF1
should be systematically screened in patients with childhood-onset severe demyelinating neu-
ropathy and additional features such as lactic acidosis, brain MRI abnormalities, and cerebellar
ataxia developing years after polyneuropathy. Neurology 2013;81:1523–1530
GLOSSARY
BNGE 5 blue native gel electrophoresis; bp 5 base pair; cDNA 5 complementary DNA; CK 5 creatine kinase; CMT 5
Charcot-Marie-Tooth; COX 5 cytochrome c oxidase; LS 5 Leigh syndrome; MNCV 5 motor nerve conduction velocities;
MRC 5 mitochondrial respiratory chain; RT 5 reverse transcription.
Peripheral neuropathies are a well-known complication of mitochondrial DNA and nuclear-
encoded mitochondrial gene mutations. For instance, patients with mutations in the nuclear-
encoded mitochondrial genesMFN2 and GDAP1, which encode outer mitochondrial membrane
proteins, usually present with axonal and demyelinating forms of Charcot-Marie-Tooth (CMT)
disease, respectively.1 Moreover, patients with mutations in the mitochondrial DNA gene
MTATP6, which encodes the ATP6 subunit of the mitochondrial respiratory chain (MRC)
complex V, may present with axonal CMT (CMT2).2
The determination of the genetic cause is a major challenge in rare neuromuscular diseases
such as autosomal recessive demyelinating CMT (CMT4). We investigated a consanguineous
family in which 2 patients with CMT4 harbored a homozygous splice site mutation in SURF1,
encoding an assembly factor of the MRC complex IV (cytochrome c oxidase [COX]). Despite
this defect, we detected some residual assembly and function of COX in fibroblasts and muscle
of both patients. We then screened for SURF1 mutations in a cohort of 40 unrelated patients
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with genetically undefined CMT4, and found
compound heterozygous SURF1 mutations in
an additional patient.
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved and performed
under the ethical guidelines issued by our institutions for clinical
studies. The diagnostic procedures were conducted according to
the Strasbourg University Hospital Ethical Committee, and
informed written consent was obtained from all patients.
CMT4 index family. We investigated a consanguineous Alger-
ian family in whom 2 patients presented with CMT4. Detailed
clinical assessments were performed on the 2 patients. Data ob-
tained included age of symptom onset, clinical history and exam-
ination findings, electrodiagnostic studies, serum creatine kinase
(CK) and lactate, and brain MRI studies.
CMT4 patient cohort. We studied 40 French families with
CMT4. Patients were considered as having CMT4 when the family
history clearly suggested an autosomal recessive pattern (multiple
affected siblings with no parent, child, or other family members
affected) or when the dominant forms of demyelinating neuropathies
had been excluded. Fifteen patients originated from consanguineous
families, and 25 patients originated from nonconsanguineous families
including 14 patients with sporadic demyelinating polyneuropathy
and 11 patients with recessive demyelinating polyneuropathy.
PMP22, MPZ, and GJB1 had been previously analyzed in all 40
patients. In addition, GDAP1, MTMR2, PRX, and SH3TC2 genes
had been screened in 20 patients.
Morphologic and biochemical analyses. Muscle and skin
biopsies were performed in the proband from the index family.
Muscle biopsy was processed with standard methods for histology
and histochemistry. Enzymatic activities of the MRC complexes
were measured in muscle and cultured fibroblasts as reported
previously.3
Molecular investigations. SURF1 (gene ID 6834, OMIM
*185620) exons 1–9 and intron/exon boundaries were amplified
and sequenced from genomic DNA from both patients of the index
family and 40 additional patients with CMT4. For reverse transcrip-
tion (RT)-PCR analysis, total RNA was isolated from cultured skin
fibroblasts of the proband from the index family using the RNeasy
Mini Kit (Qiagen GmbH, Hilden, Germany). RNA samples were
free of any contaminating DNA by treatment with the DNA-free
Kit (Ambion Inc., Austin, TX). RT of 0.8–1 mg total RNA was
performed as described.4 Amplification of SURF1 complementary
DNA (cDNA) was performed with several specific primer pairs.
Amplification products were cloned into the pCR2.1-TOPO vector
using the TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA).
Sequences of the amplification products were compared with the
GeneBank reference SURF1 sequence, NM_003172.3.
Western blot analysis. Approximately 106 cells from the pro-
band of the index family were prepared as described.5 Sodium dode-
cyl sulfate–polyacrylamide gel of 50 mg protein/lane and Western
blot analysis were performed using monoclonal antibodies against
SURF1 (MitoSciences LLC, Eugene, OR) and complex II subunit
SDHB (Invitrogen), and a polyclonal antibody against SURF1.5
Blue native gel electrophoresis. The detection of the assem-
bled respiratory chain complexes in control and proband skin fibro-
blasts was performed by using blue native gel electrophoresis
(BNGE). Samples were obtained from 23 106 cultured fibroblasts
as described.6 Twenty microliters of the sample was loaded and run
into a 5% to 13% gradient nondenaturating 1-dimension BNGE.
After electrophoresis, gels were transferred to a nitrocellulose mem-
brane (Amersham Hybond-ECL; GE Healthcare, UK). Immuno-
blotting was performed with monoclonal antibodies raised against
MTCO1 and COX4 complex IV subunits and complex II subunit
SDHA (Invitrogen).
RESULTS Characteristics of the CMT4 index family.
The 42-year-old proband was born at term after a nor-
mal pregnancy to consanguineous Algerian parents
(figure 1A). His psychomotor development proceeded
normally, with no delay in the main milestones,
including independent ambulation at the age of 12
months. He was first examined at age 8 years because
of easy fatigability. At physical examination, he pre-
sented with moderate kyphoscoliosis, moderate muscle
wasting of hands and feet, abolished tendon reflexes in
the 4 limbs, and reduced vibration and pinprick sen-
sation in the lower limbs. Electrodiagnostic studies
revealed a combination of extremely reduced conduc-
tion velocities, mildly prolonged distal latencies, and
prolonged F-wave latencies that were consistent with
severe demyelinating CMT disease (table 1). CSF
examination was normal. Superficial peroneal nerve
biopsy revealed axonal loss and hypomyelinated fibers,
consistent with severe chronic demyelinating neurop-
athy (figure 1, B and C). Eventually, the patient was
diagnosed with demyelinating CMT disease. At phys-
ical examination at age 42, the patient was still able to
walk without assistance but for no more than 30 m
because of easy fatigability. The physical examination
was similar to the previous one, indicating very slow
progression. However, he also presented with sponta-
neous unidirectional horizontal nystagmus and mild
hearing loss. Pathologic reflexes, cerebellar ataxia, dys-
tonia, and swallowing and respiratory disturbances
were not observed. Serum CK levels at rest were nor-
mal. Under fasting conditions, lactic acidosis was
observed at rest (3.3 mmol/L; normal ,1.8). Karyo-
type was normal, and the patient refused neuropsycho-
logical testing. In this patient with severe
demyelinating CMT disease, no mutations were found
in candidate genes including PMP22, MPZ, GJB1,
GDAP1, and SH3TC2. Because the patient presented
with nystagmus and hearing loss, brain MRI was per-
formed and demonstrated hyperintense lesions in both
putamina (figure 1D). Mitochondrial disease was then
suspected, and muscle and skin biopsies were per-
formed. Histologic examination of muscle showed
marked reduction of COX-specific reaction in all fibers
(figure 1E). Spectrophotometric analysis of the MRC
complexes demonstrated an isolated defect of COX
activity, with 18% of the mean control values (table 2).
The activity of the citrate synthase was normal. In
cultured fibroblasts, an isolated COX deficiency was
also detected, with 26% of the mean control values. In
both muscle and fibroblasts, complex activity ratios
were increased (I/IV, II/IV, and III/IV) or decreased
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(IV/II1 III), supporting the isolated defect of complex
IV. No pathologic variations were identified in genes
causing complex IV deficiency, including mitochon-
drial MTCO1, MTCO2, and MTCO3, and nuclear
TACO1.7
An elder sister of the patient, aged 57, presented
since before age 10 years with the same symptoms,
i.e., hands and feet wasting, abolished tendon reflexes
in the 4 limbs, and reduced vibration and pinprick sen-
sation in the lower limbs. Spontaneous unidirectional
Figure 1 Pedigree, brain imaging, peripheral nerve, skeletal muscle, and genetic analyses in the proband from
the index family
(A) Pedigree of a consanguineous family with demyelinating Charcot-Marie-Tooth disease. Black boxes indicate the patients
affected. The arrow indicates the proband. (B) Superficial peroneal nerve biopsy of proband at age 8 years. Transverse sec-
tion of the nerve showing axonal loss (*), hypomyelinated fibers (arrows), and an onion bulb formation (arrowhead) (original
magnification 31,000). (C) Superficial peroneal nerve biopsy. Electron micrograph showing axonal degeneration (*) and a
hypomyelinated degenerating fiber (arrow). Section contrasted with lead citrate and uranyl acetate (original magnification
311,925). (D) Axial T1-weighted brain MRI of the proband at age 42 years demonstrating hyperintense lesions in both
putamina (arrows). (E) Cytochrome c oxidase (COX) stain showing deficiency of COX activity in all muscle fibers of the
proband (right panel) compared with a control muscle (left panel) (original magnification3200). (F) Electropherogram show-
ing the 39 end of intron 2 from the SURF1 gene of the patient. The c.107-2A.G variation is indicated with an arrow. The
patient was homozygous for this variation.
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horizontal nystagmus, hearing loss, and kyphoscoliosis
were also observed. Electrodiagnostic studies revealed a
severe demyelinating polyneuropathy, with upper limb
motor nerve conduction velocities (MNCV) at 25 m/s.
Under fasting conditions, lactic acidosis was observed at
rest (2.9 mmol/L; normal ,1.8). Brain MRI was nor-
mal. PMP22, MPZ, GJB1, GDAP1, and SH3TC2
genes were normal. After age 40, she developed marked
cerebellar ataxia with altered finger-nose and heel-knee
tests in both sides. She refused muscle and skin biopsies.
The proband and his sister harbored a homozygous
change in SURF1 gene, the recently reported A to G
substitution (c.107-2A.G), abolishing the invariable
consensus AG splice acceptor site of intron 2 (figure 1F).8
Characteristics of another CMT4 patient harboring
SURF1 mutations. This patient was born to noncon-
sanguineous French parents, and presented at age
3 years with hands and feet wasting, abolished tendon
reflexes in the 4 limbs, and reduced vibration and pin-
prick sensation in the lower limbs. She had no family
history of neuromuscular disorders, and electrodiag-
nostic studies demonstrated severe demyelinating
polyneuropathy with upper limb MNCV at 22 m/s.
Serum CK levels at rest were normal. Under fasting
conditions, elevated plasma lactate was present at rest
(2.5 mmol/L; normal ,1.8). Brain MRI showed
nonspecific abnormalities in the brain stem periaque-
ductal area. PMP22, MPZ, GJB1, GDAP1, PRX,
SH3TC2, and MTMR2 genes were normal. Muscle
and skin biopsies were refused. After age 10, she devel-
oped mild cerebellar ataxia with altered finger-nose and
heel-knee tests in both sides. The patient was com-
pound heterozygous for 2 SURF1 variants: i) a previ-
ously reported missense change c.574C.T, resulting
in the substitution of the arginine residue at codon 192
with a tryptophan (p.Arg192Trp)9; and ii) a novel
deletion (c.799_800del). The patient inherited the
c.574C.T from her mother and the c.799_800del
from her father. The p.Arg192Trp change affects a
highly conserved residue, and is predicted to be path-
ogenic by different bioinformatics tools (Polyphen-2,
PMUT, and SIFT10–12). The c.799_800del is predicted
to produce a truncated protein (p.Leu267GlufsX24)
with an abnormal C-terminus.
Remaining patients with CMT4. SURF1 gene analysis
was normal in the remaining 39 patients with CMT4.
RT-PCR analysis. To identify the impact of the
c.107-2A.G variation on splicing, SURF1 cDNA
from the proband and a control fibroblast cell line were
amplified. Amplification of control cDNA with different
primer pairs yielded fragments of the expected sizes (895,
541, 519, and 206 base pairs [bp]) (figure 2). Sequencing
showed that the 895, 541, and 206 bp fragments corre-
sponded to SURF1 exons 1/2–9, 1/2–6, and 1/2–3/4,
Table 1 Results of nerve conduction studies in
the proband from the index family
Normal values Patient
Ulnar motor (W-BE)
Distal amplitude (mV) .4.5 3.7
Proximal amplitude (mV) 3.1
Latency (ms) ,3.4 5.2
Conduction velocity (m/s) .50 21
Ulnar sensory
Amplitude (mV) .6.0 NR
Latency (ms) ,3.2 NR
Conduction velocity (m/s) .47 NR
Ulnar F waves
Latency (ms) ,28 38
Median motor
Distal amplitude (mV) .5.6 5.1
Proximal amplitude (mV) 4.2
Latency (ms) ,4.0 5.6
Conduction velocity (m/s) .49 22
Median sensory
Amplitude (mV) .7.5 NR
Latency (ms) ,3 NR
Conduction velocity (m/s) .48 NR
Median F waves
Latency (ms) ,29 40
Tibial motor
Distal amplitude (mV) .5.9 4.2
Proximal amplitude (mV) 3.2
Latency (ms) ,6.3 7.0
Conduction velocity (m/s) .44 18
Tibial F waves
Latency (ms) ,55 62
Peroneal motor
Distal amplitude (mV) .2.3 2.2
Proximal amplitude (mV) 1.9
Latency (ms) ,5.9 6.5
Conduction velocity (m/s) .43 15
Sural sensory
Amplitude (mV) .3.5 NR
Latency (ms) ,3.8 NR
Conduction velocity (m/s) .45 NR
Abbreviations: BE 5 below elbow; ms 5 millisecond; NR 5
not recordable; W 5 wrist.
All values presented were from the left side. Motor
response amplitude was measured from baseline to peak
of the negative component.
1526 Neurology 81 October 22, 2013
ª"NFSJDBO"DBEFNZPG/FVSPMPHZ6OBVUIPSJ[FESFQSPEVDUJPOPGUIJTBSUJDMFJTQSPIJCJUFE
respectively, while the 519 bp one corresponded to
exons 2–6 (not shown). Contrariwise, cDNA samples
from the proband fibroblasts yielded several DNA frag-
ments (figure 2). Sequencing of approximately 30
cloned fragments demonstrated different SURF1 alter-
native splicing. The c.107-2A.G, affecting the invari-
ant AG dinucleotide at the acceptor splice site in intron
2, results either in exon skipping or in the use of
preexisting but weaker cryptic acceptor sites. For exam-
ple, the c.107-2A.G variation causes complete skip-
ping of exon 3 or exons 3–5, partial deletion in exon 3
(r.107_119del and r.107_189del), or insertion of in-
tronic nucleotides (r.106_107ins107-51_107-1 and
r.106_107ins107-18_107-1). Because each abnormal
transcript contains a premature termination codon,
they are either degraded by the nonsense-mediated
mRNA decay pathway or lead to truncated SURF1
proteins probably disposed by degradation. The
unavailability of biological samples from the sporadic
patient hampered further investigation.
Biochemical findings. We analyzed the SURF1 protein
byWestern blot. In mitochondria-enriched preparation
from the proband fibroblasts and in a SURF12/2 sub-
ject carrying 2 common SURF1 frameshift mutations
(p. [Leu105X] 1 [Ser282CysfsX9]) (patient 5 from
reference 13), no specific immunoreactive band was
detected using either a monoclonal (figure 3A) or a
polyclonal antibody (not shown) against SURF1, con-
firming the virtual absence of SURF1 protein in the
proband. Next, we evaluated the amount and assembly
status of COX, using 1-dimension BNGE. In the pro-
band’s fibroblasts, fully assembled COX was markedly
reduced compared with the mean value from 2 con-
trols, using both MTCO1 (18%) and COX4 (8%)
antibodies, with no evidence of subassembly species.
Again, the same findings were obtained in the
SURF12/2 control cell line, which showed slightly
more severe COX reduction (6% and 3% of the mean
control value with MTCO1 and COX4 antibodies,
respectively) (figure 3B).
DISCUSSION In our genetically undefined CMT4
cohort, we identified disease-causing SURF1 variants
in 2 of 41 families (5%), including one unrelated pro-
band in addition to the index family in which we orig-
inally found a disease-segregating SURF1 mutant
allele. This finding is relevant because molecular de-
fects are currently detected in less than 20% of CMT4
patients.14,15 In both families, a mitochondrial etiology
of the disease had not been initially considered because
the phenotype consisted of isolated peripheral neurop-
athy, with very little additional multisystem
involvement.
CMT is the most common inherited neuromuscu-
lar disorder affecting at least 1 in 2,500, and 13 genes
Table 2 Respiratory chain complex activities in muscle and fibroblasts of the proband from the index family
Muscle biopsy Cultured fibroblasts
Proband Controls (n 5 110) Proband Controls (n 5 10)
Enzyme activities
Complex I 13.9 14.1 (9.3–24.5) 5.2 7.2 (5.0–11.4)
Complex II 1 III 8.7 7.7 (4.5–12.5) 9.2 12.2 (8.3–14.1)
Complex II 19.7 18.7 (12.7–28.8) 12.6 16.7 (13.3–20.1)
Complex III 160.5 123.6 (71.0–182.9) 111.2 113.1 (95.6–139.5)
Complex IV 17.8a 101.1 (64.5–143.9) 26.6a 103.7 (93.2–122.9)
Citrate synthase 126.5 152.9 (73.9–311.3) 421.7 376.7 (253.1–459.7)
Ratios
I/II 1 III 1.58 1.83 6 0.45 0.56 0.59 6 0.12
I/III 0.09 0.11 6 0.03 0.05 0.06 6 0.01
I/IV 0.78a 0.14 6 0.03 0.20a 0.07 6 0.02
II/IV 1.11a 0.18 6 0.04 0.47a 0.16 6 0.03
III/IV 9.02a 1.22 6 0.29 4.18a 1.09 6 0.13
IV/II 1 III 2.04a 13.13 6 2.87 2.89a 8.5 6 1.46
Respiratory chain complex activities are expressed as nanomoles per minute per milligram protein and normalized for
citrate synthase activity. Control enzyme activities are given as mean with range in parentheses. Control values of activity
ratios reflecting the optimal balance between respiratory chain complex activities are given as mean 6 SD. Activities are
measured in an 800-g supernatant of crude muscle homogenates and in mitochondria-enriched preparations from cultured
fibroblasts. Mitochondria-enriched preparations were obtained as described previously.3
aAbnormal value.
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have been identified to cause autosomal recessive demy-
elinating CMT4: GDAP1, MTMR2, MTMR13,
SH3TC2, NDRG1, EGR2, PRX, HK1, FGD4, FIG4,
CTDP1, PMP22, andMPZ.15,16 Interestingly,GDAP1,
the most frequent genetic cause for CMT4, encodes a
protein anchored to the mitochondrial outer mem-
brane, thus demonstrating that mitochondrial disorders
may manifest with demyelinating polyneuropathy as
the predominant feature.1,15–17
The SURF1 gene encodes one of at least 6 assembly
factors of COX, the terminal component of the MRC.
Studies on yeast and human mutant cells indicate for
SURF1 a role in the formation of the early subcom-
plexes of COX.18 The mature SURF1 protein is a
30-kDa hydrophobic polypeptide with 2 transmem-
brane domains at the N and C termini, which anchor
the protein to the mitochondrial inner membrane.18
SURF1 mutations cause Leigh syndrome (LS), or sub-
acute necrotizing encephalomyelopathy, a severe, usu-
ally infantile encephalopathy. The MRI of LS is
characterized by symmetrical lesions in the basal gan-
glia, cerebellum, and brain stem, and the clinical course
reflects the neuropathologic hallmarks, eventually lead-
ing to global neurologic failure; lactic acidosis is almost
invariably present.8,19 Patients with SURF1-associated
LS usually exhibit a stereotypical clinical course and
mortality before 10 years of age; only a few have been
reported to survive beyond age 10.8 Only 2 atypical
patients have been reported to date: one with isolated
leukodystrophy leading to death a few months after
birth; another with isolated demyelinating polyneurop-
athy.20,21 All patients with SURF1-associated LS show
severely reduced COX activity in muscle and fibro-
blasts (5%–21% of normal values).8,13,22–25 In SURF1
null human samples, residual amounts of fully assem-
bled, functionally active complex IV were found, sug-
gesting partial functional redundancy.5 Similarly,
biochemical and assembly COX defects are also pre-
sent in SURF1 knockout mice models.26,27
All 3 patients with SURF1-associated CMT4 had
common features, including severe childhood-onset
neuropathy withMNCV,25 m/s, and lactic acidosis.
All patients had multisystem involvement with nystag-
mus, hearing loss, and kyphoscoliosis, and brain MRI
abnormalities, including putaminal and periaqueductal
Figure 2 SURF1 transcripts analysis in cultured
fibroblasts of the proband from the
index family and a control
Amplification of exons from complementary DNA was per-
formed using several primer pairs. A, Exons 1/2–9 were
amplified using the exon 1/2 (forward) primer (nucleotides
[nt] 47–65) and the exon 9 (reverse) primer (nt 941–920). B,
Exons 1/2–6 were amplified using the exon 1/2 forward
primer (nt 47–65) and the exon 6 (reverse) primer (nt
587–568). C, Exons 1/2–3/4 were amplified using the exon
1/2 forward primer (nt 47–65) and the exon 3/4 (reverse)
primer (nt 252–234). D, Exons 2–6were amplified using the
exon 2 (forward) primer (nt 69–87) and the exon 6 (reverse)
primer (nt 587–568). Nucleotide numbering uses the A of
the first ATG translation initiation start codon as nucleotide
11. Lanes 1, 3, 5, 7: patient; lanes 2, 4, 6, 8: age-matched
control. M is a 100–base pair (bp) ladder.
Figure 3 Immunoblot analysis of the proband
from the index family and controls
(A) Sodium dodecyl sulfate–polyacrylamide gel electropho-
resis of mitochondria-enriched preparations from a control
(lane 1), the proband (lane 2), and a patient previously pub-
lished carrying 2 SURF1 frameshift mutations (p.
[Leu105X]1 [Ser282CysfsX9]) used as a SURF12/2 control
(lane 3) (patient 5 of reference 13). Monoclonal antibody
against SURF1 was used and an antibody against SDHB
was used as loading control. (B) One-dimension blue native
gel electrophoresis from 2 controls (lanes 1 and 4), the pro-
band (lane 2), and the patient previously published carrying
2 SURF1 frameshift mutations (p. [Leu105X] 1 [Ser282
CysfsX9]) (lane 3). Antibodies against COX4 and MTCO1
were used to detect complex IV, and an antibody against
SDHA was used for complex II and served as loading
control.
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lesions, observed in different combinations. Two
patients had an evolving clinical course character-
ized by cerebellar ataxia, which developed several
years after the onset of the polyneuropathy.
In the c.107-2A.G samples, the absence of
SURF1 protein is associated with a detectable, but
markedly reduced, amount of fully assembled complex
IV, which is responsible for some residual COX activ-
ity. We found a slightly more severely impaired COX
assembly and reduced COX activity in a SURF1 null
LS patient (patient 5 from reference 13). It is unclear
why patients harboring SURF1 mutations, such as
those presented in this study, develop a tissue-specific
peripheral neuropathic phenotype, whereas several
other reported patients and families with similar, or
even the same, pathogenic mutations develop a multi-
system neurologic syndrome such as LS. For instance,
the c.107-2A.G associated in trans with the common
frameshift Ser282CysfsX9 was recently reported in
LS.8 In yeast strains with ablated SHY1, the SURF1
ortholog, adaptative changes with interacting partners
(i.e., other COX assembly factors or cytochrome c),
and/or adaptive mechanisms such as increased mito-
chondrial copper level can suppress, at least in part, the
COX defect.28 Likewise, the variable severity of the
phenotype associated with the virtual absence of
SURF1 may well depend on the efficiency of compen-
satory genetic or epigenetic mechanisms in humans.
The patients with SURF1-associated CMT4 re-
ported herein presented with a mainly demyelinating
polyneuropathy, although axonal loss was also observed.
The precise molecular mechanisms linking MRC dys-
function to axonal loss and demyelination have yet to be
determined, although studies on CMT-causing genes
encoding mitochondrial molecules such as GDAP1,
MFN2, andMRS2 suggest that perturbed axonal trans-
port, impaired energy production, and/or defective
mitochondrial Mg21 homeostasis may be involved.29,30
We suggest that SURF1 should be considered in the
molecular diagnostic evaluation of patients with
CMT4. The clinical and electrophysiologic phenotype
in our families was typical of CMT4; however, the fol-
lowing features should help to prioritize SURF1 for
mutation analysis in patients with demyelinating neu-
ropathy: 1) disease onset in the first decade; 2) variable
clinical severity; 3) associated features including nystag-
mus, hearing loss, and kyphoscoliosis; 4) brain MRI
abnormalities, including putaminal hyperintense lesions
and periaqueductal abnormalities; 5) lactic acidosis; and
6) an evolving clinical phenotype with cerebellar ataxia
developing several years after polyneuropathy onset.
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